ADAM30 is a metalloprotease belonging to the ADAM (A disintegrin and metalloprotease) family that plays a crucial role in amyloid precursor protein (APP) metabolism and neurological processes 1. The primary function involves lysosomal APP processing, where ADAM30 cleaves and activates cathepsin D (CTSD), leading to APP degradation and reduced amyloid-β (Aβ) peptide production 1. This mechanism requires both CTSD activation and APP sorting to lysosomes 1. ADAM30 expression is significantly decreased (~50%) in Alzheimer's disease brains, inversely correlating with amyloid load 1. In transgenic Alzheimer's mouse models, neuronal ADAM30 overexpression reduces Aβ42 secretion, lowers brain amyloid plaque burden, enhances CTSD activity, and rescues long-term potentiation deficits 1. ADAM30 shows testis-specific expression and maps to human chromosome 1-13 2. The protein has been identified as a potential therapeutic target for Alzheimer's disease alongside other ADAM family members 3. Additionally, ADAM30 may serve as a biomarker in endometrial carcinoma, where it is overexpressed in cancer tissues 4, and has been identified as a possible target protein for prostate cancer aptamers 5.